Guardant Health, Inc. (NASDAQ:GH) Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its position in Guardant Health, Inc. (NASDAQ:GH) by 64.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 23,661 shares of the company’s stock after acquiring an additional 9,283 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Guardant Health were worth $543,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after purchasing an additional 796 shares in the last quarter. Oak Ridge Investments LLC increased its holdings in shares of Guardant Health by 8.5% in the 1st quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock valued at $382,000 after purchasing an additional 1,451 shares in the last quarter. Quarry LP purchased a new position in shares of Guardant Health in the 2nd quarter valued at about $44,000. Green Alpha Advisors LLC increased its holdings in shares of Guardant Health by 23.6% in the 3rd quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company’s stock valued at $201,000 after purchasing an additional 1,674 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its holdings in shares of Guardant Health by 4.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 41,450 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on GH shares. TD Cowen increased their price target on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. The Goldman Sachs Group raised their target price on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Leerink Partners dropped their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Craig Hallum raised their target price on shares of Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America raised their target price on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, July 18th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average target price of $40.31.

Guardant Health Price Performance

GH opened at $21.79 on Wednesday. The company’s 50 day simple moving average is $23.49 and its 200 day simple moving average is $25.66. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $37.04. The stock has a market capitalization of $2.67 billion, a PE ratio of -5.56 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The company had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. During the same period in the prior year, the business posted ($0.67) earnings per share. Guardant Health’s revenue was up 29.2% on a year-over-year basis. As a group, sell-side analysts expect that Guardant Health, Inc. will post -3.31 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.